First in Human Results Presented at EuroPCR with Simultaneous Publication in EuroIntervention
Key Highlights:
1. The DurAVR™ Transcatheter Heart Valve (THV) First-in-Human Study demonstrated promising haemodynamic performance sustained to 1 year and restoration of nearnormal blood flow dynamics.
2. DurAVR™ THV demonstrated an outstanding safety profile: No mortality (all causes), no disabling stroke, no life-threatening bleeding, and no myocardial infarction were reported during any follow-up visits.
3. These encouraging preliminary First-in-Human study results will be further validated in an FDA-approved Early Feasibility Study (EFS) commencing soon
...nice confirmation for team AVR...
First in Human Results Presented at EuroPCR with Simultaneous...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $326.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $167.9K | 9.871K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1460 | $17.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.10 | 1 | 1 |
View Market Depth
| Last trade - 13.54pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |